Travel Resources

Air Care Alliance helps cancer patients travel to distant health centers for care. You may call ACA at 1-888-662-6794 tollfree in the U.S. Direct number 757-318-9145, or visit their web site at http://www.angelflightfla.org/aircareall.org/acahome.html.

The American Cancer Society (ACS) sponsors Hope Lodges, which provide free lodging for those who travel to receive cancer care. Check your local phone book, or visit their web site at http://www.cancer.org/frames.html.

The Candlelighters Childhood Cancer Foundation can help you make travel arrangements. In the U.S., call (301) 657-8401 or 1-800-366-CCCF. In Canada, call 1-800-363-1062. Also on the Web at http://www.candlelighters.org.

Corporate Angel Network helps cancer patients travel to distant health centers for care. Call (914) 328-1313, or visit their web site at http://www.corpangelnetwork.org/.

The Leukemia Society of America will reimburse up to $750 per year in travel expenses. Call 1-800-955-4LSA, or visit their web site at http://www.leukemia.org/

Mercy Medical Airlift helps cancer patients travel to distant health centers for care. Call 1-800-296-1191, or visit http://www.mercymedical.org.

National Association of Hospital Hospitality Houses (NAHHH) can recommend nearby hotels with reduced rates for cancer patients. Call (301) 961-3094, (317) 883-2226, or 1-800-542-9730; or visit http://visit-usa.com/hhh/members.htm.

The National Cancer Institute, Bethesda, Maryland, will in some cases help pay for the travel and lodging expenses of those being treated at the NCI. Call 1-800-4-CANCER.

Ronald McDonald House Coordinator, c/o McDonalds Corporation, provides free lodging for children who are being treated for cancer. Call (630) 623-7048, or visit http://www.mcdonalds.com/a_community/.

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap